Acrivon Therapeutics shares surge 10.46% intraday after Zacks Rank upgrades to Buy on improved earnings outlook.

Acrivon Therapeutics surged 10.46% intraday after Zacks upgraded the stock to a "Buy" rating, citing improved earnings expectations. The move coincided with positive developments, including the FDA’s Fast Track Designation for ACR-368 in treating platinum-resistant ovarian and endometrial cancers, announced in May. This regulatory boost, combined with the upgrade, signaled growing confidence in the company’s pipeline and therapeutic potential. Additionally, recent product advancements, such as the dual WEE1 and PKMYT1 inhibitor ACR-2316 and strategic leadership hires, reinforced investor optimism. The intraday rally reflected a confluence of analyst upgrades and regulatory progress, highlighting Acrivon’s advancing oncology-focused drug development.